ESK-001

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uveitis Posterior Non-Infectious

Conditions

Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis

Trial Timeline

Jun 14, 2023 → Aug 13, 2024

NCT ID

NCT05953688

About ESK-001

ESK-001 is a phase 2 stage product being developed by Alumis for Uveitis Posterior Non-Infectious. The current trial status is terminated. This product is registered under clinical trial identifier NCT05953688. Target conditions include Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis Posterior Non-Infectious were approved

Approved (3) Terminated (8) Active (9)

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

✅Ixekizumab Prefilled SyringeEli LillyApproved

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

✅AdalimumabAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06952634	Phase 1	Recruiting	Apr 29, 2025	Dec 1, 2025	Hepatic Impairment
NCT06962774	Phase 1	Completed	Apr 23, 2025	Aug 1, 2025	Renal Impairment
NCT05953688	Phase 2	Terminated	Jun 14, 2023	Aug 13, 2024	Uveitis Posterior Non-Infectious
NCT05739435	Phase 2	Active	Jan 17, 2023	Dec 30, 2026	Plaque Psoriasis

Competing Products

20 competing products in Uveitis Posterior Non-Infectious

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
Myfortic	Novartis	Pre-clinical	22
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AEB071	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35